Mar 26 |
United States Food & Drug Administration (FDA) Notifies Mesoblast that Available Clinical Data from Phase 3 Trial Appear Sufficient to Support BLA Submission for Remestemcel-L in Children with Steroid-Refractory Acute Graft Versus Host Disease (SR-aGVHD)
|
Mar 13 |
Mesoblast Successfully Completes Placement and Accelerated Entitlement Offer
|
Mar 11 |
Why Fangdd Network Group Shares Are Trading Higher By Around 78%; Here Are 20 Stocks Moving Premarket
|
Mar 11 |
Biggest stock movers today: Crypto-linked stocks, MESO and more
|
Mar 10 |
United States Food & Drug Administration (FDA) Supports Accelerated Approval Pathway for Rexlemestrocel-L in End-Stage Heart Failure Patients with a Left Ventricular Assist Device (LVAD)
|
Feb 29 |
Mesoblast Limited (MESO) Q2 2024 Earnings Call Transcript
|
Feb 29 |
Mesoblast Limited 2024 Q2 - Results - Earnings Call Presentation
|
Feb 29 |
Mesoblast First Half 2024 Earnings: EPS Beats Expectations, Revenues Lag
|
Feb 28 |
Mesoblast GAAP EPS of -$0.038 beats by $0.76, revenue of $3.39M misses by $0.41M
|
Feb 28 |
Mesoblast Reports Financial Results and Operational Update for Half-Year Ended December 31, 2023
|